The MDL is meant to centralize all semaglutide lawsuits involving gastroparesis injuries into one court, under one judge: Each lawsuit contains substantially similar allegations about GLP-1 RAs (specifically, Ozempic, Wegovy, Rybelsus, Trulicity, and/or Mounjaro) and their alleged propensity to cause gastrointestinal injuries. All of these lawsuits share common issues of fact regarding: If defendants knew or should have known that their GLP-1 RA products can cause gastroparesis and other gastrointestinal injuries Whether defendants adequately warned plaintiffs or their prescribing physicians about the alleged dangers of these products Whether defendants made false, misleading, or incomplete representations regarding the safety of these products
It helps reduce appetite, increase feelings of fullness, and improve metabolic health
Notably, long-acting, human GLP-1 analogs (e.g
S.AguilaM
Some swear by its hair-reviving powers, while others dismiss it as overhyped
It must be taken on an empty stomach upon waking with a small sip of water (up to 120 ml), then waiting at least 30 minutes before consuming any food, drink, or other oral medications